Pricing Log in Create free account

MeiraGTx Holdings PLC (MGTX) vs Prime Medicine, Inc. (PRME)

MeiraGTx Holdings PLC and Prime Medicine, Inc. are both Biotechnology companies. MeiraGTx Holdings PLC and Prime Medicine, Inc. are of similar size ($817.3M and $807.1M). Prime Medicine, Inc. has negative trailing earnings, so its P/E is not meaningful; MeiraGTx Holdings PLC trades at 11.8×. MeiraGTx Holdings PLC grew revenue faster over the last twelve months: 948.4% against −17.9%. MeiraGTx Holdings PLC has the higher net margin (19.9% vs −4,613.1%) and the higher return on invested capital (66.6% vs 0.00%). Across the 17 metrics below, MeiraGTx Holdings PLC leads on 15 and Prime Medicine, Inc. on 2.

Valuation

Metric MGTX PRME Biotechnology median
P/E 11.83 n/m 10.60
P/S 2.07 200.59 9.40
P/B 3.81 20.52 2.13
Price to free cash flow 81.19 n/m 25.18
EV/EBITDA 3.94 n/m 0.66
EV/Sales 1.96 177.25 9.02
Earnings yield 8.45% (23.95%) (32.88%)
Free cash flow yield 1.23% (19.20%) (23.13%)

Profitability

Metric MGTX PRME Biotechnology median
Gross margin 97.95% 100.00% 68.51%
Operating margin 46.30% (4,824.94%) 0.00%
Net margin 19.87% (4,613.11%) 0.00%
Free cash flow margin 2.55% (3,850.92%) 0.00%
Return on equity 72.22% (373.29%) (51.96%)
Return on assets 26.54% (71.16%) (46.06%)
Return on invested capital 66.60% 0.00% 0.00%

Growth

Metric MGTX PRME Biotechnology median
Revenue growth (TTM) 948.35% (17.90%) 6.76%
EPS growth (last fiscal year) 33.02% 18.18% 29.88%
Revenue growth, 5-year CAGR 39.22% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MGTX PRME Biotechnology median
Debt to equity 0.46 0.00 0.00
Current ratio 3.76 3.05 4.97
Net debt to EBITDA 0.18 0.88 1.01

Dividend

Metric MGTX PRME Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric MGTX PRME Biotechnology median
Market cap 817.32m 807.12m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack